Actinium Pharma unveils groundbreaking data on radiotherapy platform at AACR 2026
The presentations will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies
